Methylphenidate in the management of cancer-related fatigue.
Patrick C Stone
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2372-2373 (2013-05-22)
Evert J Semeijn et al.
Journal of the American Geriatrics Society, 61(6), 882-887 (2013-05-29)
To increase insight into the effect of attention-deficit/hyperactivity disorder (ADHD) on health in general in older adults. Two-phase sampling side-study. Longitudinal Aging Study Amsterdam (LASA). Two hundred twenty-three randomly selected LASA respondents. Information was collected during home visits on physical...
Eduardo Bruera et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2421-2427 (2013-05-22)
Cancer-related-fatigue (CRF) is common in advanced cancer. The primary objective of the study was to compare the effects of methylphenidate (MP) with those of placebo (PL) on CRF as measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue...
Alice Charach et al.
Pediatrics, 131(5), e1584-e1604 (2013-04-03)
The US Agency for Healthcare Research and Quality sponsored a comparative effectiveness review of interventions for preschoolers at risk for attention-deficit/hyperactivity disorder (ADHD). Medline, Cochrane CENTRAL, Embase, PsycInfo, and Education Resources Information Center were searched from 1980 to November 24...
Sucharita S Somkuwar et al.
Biochemical pharmacology, 86(2), 309-316 (2013-04-30)
Attention deficit/hyperactivity disorder (ADHD) is attributed to dysfunction of the prefrontal cortex. Methylphenidate, an inhibitor of dopamine and norepinephrine transporters (DAT and NET, respectively), is a standard treatment for ADHD. The Spontaneously Hypertensive Rat (SHR) is a well-established animal model...